B Robert Mozayeni, MD
Founder and General Medical Director
Internal Medicine, Rheumatology, Vascular Inflammatory Diseases
Dr. B. Robert Mozayeni is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a co-founder of the Foundation for the Study of Inflammatory Diseases. And, he recently joined as a founding Board member, the Human-Kind Alliance. He serves as an advisor to Pharma- and Nutra-ceutical companies and serves on an Institutional Review Board specializing in nutraceutical products for pain management.
In the Fall or 2017, he became the President-Elect of ILADS and will assume the role of ILADS President for 2 years starting in the Fall of 2019. His main objective with ILADS is the same as with his professional career – to advance the science of translational medicine. His career passion is to find the fastest path for advancing medical science in diverse areas of patient need to validate and continuously improve best clinical practices – all to alleviate medical suffering faster while reducing the cost of care. By studying how to advance best practices, while understanding and navigating the controversies in diverse areas of medical need, insights are gained in one arena that can inform translational medical science in another.
Recently, Dr. Mozayeni launched T Lab Inc., a research and clinical laboratory engaged in research using advanced microscopy to understand better the pathogenesis of disease in inflammatory conditions associated with persistent infections. Using advanced microscopy and molecular labelling methods, this lab will soon provide clinical testing to address unmet needs in patients suspected to have chronic illness from persistent inflammatory disorders.
He was trained as a medical scientist and has deep experience in multiple clinical and health policy areas and broad experience over the entire biomedical and health industry. He has special research and clinical expertise with regard to autoimmune diseases and the effects of chronic infection and inflammation on vascular physiology and neurovascular conditions seen commonly with autoimmune and neurovascular diseases. With a strong foundation in the basic sciences and evidence-based medicine, he analyzes complex medical cases using a combination of basic scientific principles and clinical experience along with the balance of the evidence base. This approach often helps find the root cause of a condition and the way out for complex medical problems. His traditional medical science background is enhanced by clinical experience in functional and integrative medicine.
He is experienced and astute regarding evidence-based medicine and the use of all available computational methods in statistics and probability science to collect medical evidence. He observes that evidence-based medicine rigorously considers patient preference to improve outcomes. Therefore, he seeks to fully understand the data and differing points of view about a particular approach and provide the patient with the best available personalized advice. He has been developing knowledge systems that consider all available evidence and accelerate clinical trials to improve patient care in his practice and nationwide.
Dr. Mozayeni is an honors graduate of the accelerated Leadership in Medicine Program of Union College and Albany Medical College. As an undergraduate, he had an interest in government and health policy – he had a minor in Political Science and worked on Capitol Hill in the office of Hon. Albert Gore, Jr. He received his MD degree from Albany Medical College. His honors included: Pew Foundation Scholar in the Transplantation Immunology Laboratory, Alpha Omega Alpha Honor Medical Society, and one of the first Research Scholars of the Howard Hughes Medical Institute at the National Institutes of Health.
He pursued his clinical training at Yale and the NIH. He was an intern and resident in Internal Medicine at Yale-New Haven Hospital and was a Fellow in Rheumatology with the Yale School of Medicine. While at Yale, Dr. Mozayeni was in the Physician-Scientist research residency program and thus, held a simultaneous position as a Fellow in the Department of Molecular Biophysics and Biochemistry. He studied the molecular basis of autoimmune diseases and as a result received a competitive NIH Physician-Scientist Training Award.
Subsequently, he moved to NIH to accept a tenure-track appointment as Senior Staff Fellow in the National Heart Lung and Blood Institute and a clinical appointment as Rheumatology Fellow in the National Institute of Arthritis and Musculoskeletal Diseases. He has been a member of the American College of Physicians and a Fellow of the American College of Rheumatology.
Dr. Mozayeni has published numerous papers on immunology and cerebrovascular blood flow hemodynamics. He has presented his work in numerous US and International talks. He holds over 8 US and international patents with the greatest concentration of his work on methods related to evaluation of brain blood flow. In the past 4 years, he has been actively researching and publishing his work on chronic rheumatic diseases and their relationship to persistent human Bartonella spp.infection. He has published 4 papers on this in the past 2 years, and one of these includes the largest case series by far, of persistent Bartonella spp. infection in humans (see news item). Of note, chronic persistent Bartonella spp. infections are strongly associated with neurovascular diseases. Thus, Dr. Mozayeni is uniquely qualified in the combined areas of chronic persistent endovascular infections and related rheumatological and neurovascular diseases. He has also published papers providing new insights as to a potential infectious (Bartonella spp.) cause of osteoarthritis and also, a case of arthritis associated with hypermobility that was likely caused by Bartonella spp.
He has founded three Washington DC Area biotechnology companies, one of which develops systems to improve the use of medical evidence by patients and practitioners to accelerate the process of medical innovation and translation to practice. This translational science aims to help people benefit as soon as appropriate using combined skills and tools in the areas of information science, regulatory affairs, legislative affairs, medical evidence, patient informed consent, and most importantly, patient preference.
He is a past member of the Board of Directors of the International Hyperbaric Medical Foundation 501(c)3 and, subsequently, the International Hyperbaric Medical Association 501(c)4. In both capacities over 10 years, he worked pro-bono to advance the cause of treating brain injury in Veterans where he conceived and directed an observational study of treating brain injury using hyperbaric oxygen.
Dr. Mozayeni previously held hospital privileges at Yale-New Haven Hospital, the NIH Clinical Center, and subsequently, since 1994, has clinical privileges at Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.
On a personal note, Dr. Mozayeni is a compassionate physician who listens very carefully to his patients – he believes that in a patient’s history lies the most valuable form of medical information and provides the key to their proper diagnosis and treatment. Natural remedies, particularly when they have a chance to be curative, are always reviewed with patients before considering symptomatic interventions. You will be given a fair and unbiased view of all available treatments with all available evidence and risk / benefit considerations, to give you sufficient information to make an informed decision about your health direction.